# How to Assess Risk of Bias in Randomized Controlled Trials

## Quick Answer

- Use the Cochrane Risk of Bias tool to judge each randomized controlled trial across five core domains: randomization, deviations from intended interventions, missing outcome data, outcome measurement, and selection of reported results.
- Make each domain judgment as low risk, some concerns, or high risk based on explicit criteria, then combine domain judgments into an overall risk of bias rating for the study.
- The tool assesses internal validity only, so a low risk of bias rating does not guarantee that the study findings apply to your specific animal production setting.

## Understanding Risk of Bias in Randomized Controlled Trials

Risk of bias refers to systematic errors in a study that can make its results differ from the true effect. In randomized controlled trials, bias can enter at multiple points, from how animals are allocated to treatment groups to how outcomes are measured and reported. The Cochrane Risk of Bias tool provides a structured framework for evaluating these potential sources of error.

For animal farming research, this assessment matters because management decisions often depend on trial results. If a feeding trial, vaccine efficacy study, or housing comparison has high risk of bias, the conclusions may not hold when applied to your operation. The tool helps you distinguish between studies that provide reliable evidence and those that require caution.

The current version of the tool, often called RoB 2, was developed for randomized trials and focuses on the effect of assignment to intervention. This means it evaluates whether the randomization process itself, instead of subsequent management decisions, produced the observed outcomes. Understanding this distinction is important when you apply the tool to livestock research where animals may be moved, treated, or culled during the trial period.

## The Five Domains of the Cochrane Risk of Bias Tool

The Cochrane Risk of Bias tool organizes assessment around five specific domains. Each domain targets a different stage of the trial where bias can enter. You evaluate each domain separately before making an overall judgment about the study.

### Domain 1: Randomization Process

The first domain examines whether the allocation sequence was truly random and whether allocation was concealed until animals were assigned to groups. A proper randomization process ensures that each animal has an equal chance of being assigned to any treatment group, which helps balance known and unknown confounding factors.

Key questions for this domain include whether the allocation sequence was generated using a valid random method, such as a random number table or computer-generated sequence. You also need to assess whether the person enrolling animals into the study could have known or predicted the next assignment. If allocation is not concealed, the person enrolling animals might consciously or unconsciously influence which animals enter which group.

In animal trials, common problems include alternating assignments, assigning animals based on ear tag number, or using date of birth to determine group membership. These methods are not truly random and can introduce selection bias. For example, if heavier animals tend to be born earlier in the calving season and you assign by birth date, you may inadvertently place heavier animals in one treatment group.

### Domain 2: Deviations from Intended Interventions

This domain assesses whether the interventions were delivered as planned and whether any deviations from the intended protocol could have affected outcomes. In animal research, deviations can occur when animals are removed from their assigned treatment, when treatments are given incorrectly, or when co-interventions differ between groups.

The tool distinguishes between deviations that arise from the experimental setting and those that reflect real-world conditions. For trials where the effect of assignment is the focus, you consider whether deviations from the intervention occurred after randomization and whether these deviations were balanced between groups.

Blinding is a critical consideration in this domain. If the people caring for the animals know which treatment each animal receives, they may unconsciously treat groups differently. For example, a stockperson who knows which pigs receive an experimental feed additive might observe them more closely or handle them differently. Blinding of animal caretakers and outcome assessors helps prevent these performance biases.

### Domain 3: Missing Outcome Data

The third domain examines whether outcome data are complete for all animals that were randomized. Missing data can arise when animals die, are removed from the study, or when measurements are not recorded. If missing data are related to both the treatment and the outcome, the results can be biased.

For example, in a mastitis treatment trial, if cows that fail to respond to treatment are more likely to be culled and therefore missing from the final assessment, the remaining data may overstate the treatment effect. You need to consider whether the proportion of missing data is similar across groups and whether the reasons for missingness are related to the true outcome.

The tool asks you to judge whether data for each outcome were likely to be missing, and if so, whether the missingness depended on the true value of the outcome. Statistical methods such as multiple imputation or sensitivity analyses can address missing data, but you should assess whether the trial authors used appropriate methods.

### Domain 4: Measurement of the Outcome

This domain evaluates whether the outcome measurement method was appropriate and whether the measurement could have been influenced by knowledge of the intervention received. Outcomes can be measured objectively, such as weight gain or milk production, or subjectively, such as lameness scores or body condition scores.

Objective outcomes measured by calibrated equipment are generally at lower risk of bias than subjective assessments. However, even objective measurements can be influenced if the person recording them knows the treatment assignment and has expectations about the results.

For subjective outcomes, blinding of outcome assessors is particularly important. If the person scoring lameness knows which animals received the hoof treatment being tested, their expectations might influence their scores. The tool asks whether the outcome assessor was blinded to intervention status and whether the measurement method was appropriate for the outcome being assessed.

### Domain 5: Selection of the Reported Result

The final domain examines whether the reported results were selected from multiple analyses or multiple outcome measurements. Trials can generate many possible results, and if authors report only the analyses that show statistically significant effects, the published results may not represent the full picture.

You need to consider whether the trial was analyzed according to a pre-specified plan and whether all measured outcomes were reported. If the trial protocol or statistical analysis plan is available, you can compare the reported results with the planned analyses. Discrepancies between planned and reported analyses raise concerns about selective reporting.

In animal research, this domain also covers situations where multiple time points were measured but only some are reported, or where multiple outcome definitions were used but only the most favorable is presented. The availability of trial registries and published protocols makes this assessment easier for recent trials.

## Making Domain Judgments

For each domain, you assign one of three judgments: low risk of bias, some concerns, or high risk of bias. These judgments are based on your answers to the signaling questions within each domain.

### Signaling Questions and Algorithms

Each domain includes a set of signaling questions that guide your assessment. These questions are designed to elicit specific information about the trial methods. Your answers to these questions feed into an algorithm that determines the domain-level judgment.

For example, in the randomization domain, the signaling questions ask whether the allocation sequence was random, whether the sequence was concealed until animals were assigned, and whether baseline differences between groups suggest a problem with randomization. If you answer yes to the first two questions and no to the third, the algorithm produces a low risk of bias judgment for that domain.

You should answer each signaling question based on the information reported in the trial publication. If the trial report does not provide enough information to answer a question, you should mark the question as no information and consider whether this lack of detail affects your confidence in the domain judgment.

### Combining Domain Judgments

After judging each of the five domains, you combine them into an overall risk of bias judgment for the study. The overall judgment is determined by the domain with the highest level of concern. If any domain is judged as high risk of bias, the overall judgment is high risk. If one or more domains raise some concerns but none are high risk, the overall judgment is some concerns. Only when all domains are judged as low risk is the overall judgment low risk.

This conservative approach reflects the principle that a trial is only as strong as its weakest component. A study with excellent randomization but poor blinding of outcome assessors may still produce biased results for subjective outcomes.

## At a Glance: Risk of Bias Judgment Summary

| Domain | Key Question | Low Risk Example | High Risk Example |
|--------|-------------|------------------|-------------------|
| Randomization Process | Was allocation truly random and concealed? | Computer-generated sequence with opaque envelopes | Alternating assignment by pen location |
| Deviations from Intended Interventions | Were interventions delivered as planned and were groups treated equally? | Blinded caretakers with protocol adherence checks | Unblinded staff who provide extra care to one group |
| Missing Outcome Data | Were outcome data complete and missingness unrelated to true outcome? | Low and balanced attrition with sensitivity analysis | High attrition in treatment group due to treatment failure |
| Measurement of the Outcome | Was the outcome measured appropriately and was the assessor blinded? | Calibrated scales with blinded technician | Subjective lameness scoring by unblinded veterinarian |
| Selection of the Reported Result | Were all planned analyses and outcomes reported? | Analysis matches pre-registered protocol | Only significant time points reported from multiple measurements |

## Practical Steps for Assessing a Trial

When you sit down to assess a randomized controlled trial using the Cochrane Risk of Bias tool, follow a systematic process. This approach ensures consistency and helps you document your judgments for transparency.

### Step 1: Gather the Necessary Documents

Before you begin the assessment, collect the trial publication, the trial protocol if available, and any supplementary materials. The protocol is particularly valuable because it allows you to compare planned methods with what was actually done. Trial registrations can also provide information about pre-specified outcomes and analyses.

For animal trials, you may also need to check whether the study followed relevant reporting guidelines. The [EQUATOR Network](https://www.equator-network.org/) maintains a comprehensive collection of reporting guidelines for health research, including those relevant to animal studies. Consulting these guidelines can help you understand what information should have been reported and identify gaps in the trial publication.

### Step 2: Read the Trial Methods Carefully

Read the methods section of the trial publication with attention to the details relevant to each domain. Look for explicit statements about randomization methods, allocation concealment, blinding, sample size calculations, and statistical analysis plans. Note any information that is missing or ambiguous.

Pay particular attention to how the trial describes animal management during the study. Details about housing, feeding, health care, and removal criteria are relevant to several domains. If the methods section does not describe these aspects, you may need to contact the authors or look for supplementary materials.

### Step 3: Answer the Signaling Questions

Work through each domain in order, answering the signaling questions based on the information you have gathered. Record your answers and note the evidence that supports each answer. If you cannot determine an answer from the available information, mark it as no information and consider the implications.

Be careful to distinguish between what the authors claim and what they actually describe. A statement that the trial was randomized does not tell you how randomization was performed. Look for specific descriptions of the randomization method and allocation concealment procedures.

### Step 4: Make Domain Judgments

Use the algorithm for each domain to convert your signaling question answers into a domain judgment. Document the reasons for each judgment, including the specific evidence that supports your decision. This documentation is important for transparency and for resolving disagreements among reviewers.

### Step 5: Determine the Overall Judgment

Combine the domain judgments to determine the overall risk of bias for the trial. Remember that the overall judgment reflects the highest level of concern across all domains. Record the overall judgment and the rationale for it.

### Step 6: Document Your Assessment

Record your assessment in a format that can be shared with others. Many systematic reviews use a risk of bias table that summarizes the judgment for each domain and the overall judgment. Include the supporting evidence for each judgment so that readers can understand your reasoning.

## Common Failure Patterns in Animal Trials

Certain methodological weaknesses appear frequently in animal research trials. Recognizing these patterns helps you assess trials more efficiently and identify potential sources of bias.

### Inadequate Randomization Methods

Many animal trials describe themselves as randomized but do not provide details about the randomization method. Some use quasi-random methods such as alternation, which does not provide true random allocation. Others may randomize at the group level, such as by pen or paddock, but analyze at the individual animal level without accounting for clustering.

When animals are randomized in groups, the effective sample size is smaller than the number of animals. This clustering effect must be considered in the analysis. If the trial authors did not account for clustering, the results may overstate precision and the risk of bias may be higher than it appears.

### Lack of Blinding

Blinding is often difficult in animal trials, particularly when treatments involve different management practices. However, the absence of blinding can introduce bias, especially for subjective outcomes. Some trials attempt to blind outcome assessors even when animal caretakers cannot be blinded, which reduces but does not eliminate the risk.

For example, a trial comparing two feeding systems may not be able to blind the stockpersons who manage the animals, but the person weighing the animals or collecting blood samples can be blinded to treatment assignment. When assessing this domain, consider whether any blinding was used and whether the outcomes are likely to be influenced by knowledge of treatment.

### High and Differential Attrition

Animal trials often experience attrition due to death, culling, or removal from the study. If attrition is high or differs between treatment groups, the results may be biased. Differential attrition is particularly concerning when the reasons for removal are related to the treatment or the outcome.

For instance, in a trial of a new vaccine, if more animals in the control group die from the disease being studied, the surviving control animals may be healthier than the original control group. This can bias the comparison in favor of the vaccine. Assess whether the trial authors reported reasons for attrition and whether they conducted analyses that account for missing data.

### Selective Outcome Reporting

Some trials measure multiple outcomes but report only those with statistically significant results. Others may analyze outcomes at multiple time points but report only the time points that show effects. This selective reporting can create a misleading picture of the treatment effect.

Comparing the reported outcomes with the trial protocol or registration can reveal selective reporting. If no protocol is available, you may need to assess whether the reported outcomes seem to be a subset of what would reasonably have been measured.

## Recording Your Assessments

Systematic recording of risk of bias assessments is essential for transparency and reproducibility. Your records should allow another researcher to understand your judgments and the evidence that supports them.

### Risk of Bias Tables

A risk of bias table typically lists each domain in rows and provides columns for the judgment, the supporting evidence, and any quotes from the trial that support your judgment. The table may also include the overall judgment for the trial.

For animal trials, you may want to include additional columns for details specific to the study, such as the species, production system, and outcome measures. This context helps readers understand the applicability of the trial results to their own settings.

### Supporting Evidence and Quotations

For each judgment, record the specific evidence from the trial that supports your decision. Direct quotations from the trial publication can be useful, particularly for methods descriptions. If you contacted the authors for additional information, record the date and content of that communication.

Your documentation should distinguish between what the trial reported and what you inferred. If you made assumptions because information was missing, state those assumptions explicitly. This transparency allows others to challenge your judgments if they disagree.

## Using Risk of Bias Assessments in Systematic Reviews

Risk of bias assessments serve multiple purposes in a systematic review. They inform the synthesis of results, the interpretation of findings, and the certainty of the evidence.

### Informing the Synthesis

Trials with high risk of bias may be excluded from the primary analysis or included in sensitivity analyses. Many systematic reviews present results stratified by risk of bias, allowing readers to see whether conclusions change when only low risk of bias trials are considered.

If you find that the treatment effect differs between low and high risk of bias trials, this difference suggests that bias may be influencing the results. This finding should be discussed in the review and considered when making recommendations.

### Interpreting Findings

Risk of bias assessments help you interpret the strength of the evidence. A meta-analysis that includes only low risk of bias trials provides stronger evidence than one that includes trials with serious methodological limitations. Your conclusions should reflect the confidence you have in the underlying studies.

When the evidence base includes trials with varying risk of bias, you should consider whether the results are consistent across trials of different methodological quality. Inconsistent results may indicate that bias is affecting the findings or that the treatment effect varies across settings.

### Considering Certainty of Evidence

Risk of bias is one of several factors that determine the certainty of evidence. Other factors include imprecision, inconsistency, indirectness, and publication bias. Frameworks such as GRADE incorporate risk of bias assessments into an overall rating of the certainty of evidence for each outcome.

For animal production research, considering the certainty of evidence helps you decide how much confidence to place in the findings. If the evidence is of low certainty, you may need to make management decisions with less confidence and monitor outcomes closely.

## Limitations of the Cochrane Risk of Bias Tool

The Cochrane Risk of Bias tool is a valuable instrument, but it has limitations that you should recognize when using it.

### Focus on Internal Validity

The tool assesses internal validity, meaning whether the trial results are likely to reflect the true effect in the study population. It does not assess external validity, which concerns whether the results apply to other populations or settings. A trial can have low risk of bias but still not apply to your specific production system.

For example, a feeding trial conducted in a research herd with intensive management may have low risk of bias but may not apply to a pasture-based system with different genetics, nutrition, and disease pressures. You need to consider applicability separately from risk of bias.

### Reliance on Reporting Quality

The tool depends on the information reported in the trial publication. If the authors did not describe their methods adequately, you may not be able to judge the risk of bias accurately. Poor reporting does not necessarily mean the trial was conducted poorly, but it does limit your ability to assess it.

Reporting guidelines can help address this problem by encouraging authors to provide complete descriptions of their methods. The [EQUATOR Network](https://www.equator-network.org/) provides access to reporting guidelines that cover various study types, and using these guidelines during trial design and reporting can improve the transparency of animal research.

### Complexity and Time Requirements

Applying the tool requires careful reading and judgment, which takes time. For systematic reviews with many trials, the assessment process can be resource intensive. Some reviewers use abbreviated versions of the tool or focus on the domains most relevant to their review question.

Despite these limitations, the structured approach of the Cochrane tool provides a more rigorous assessment than informal judgments about study quality. The tool forces you to consider specific sources of bias and to document your reasoning.

## Professional Escalation Criteria

When you encounter specific situations during risk of bias assessment, you may need to escalate your concerns or seek additional input.

### When to Contact Trial Authors

If the trial publication lacks essential information about methods, you may contact the authors to request clarification. This is particularly useful when the missing information is critical for your assessment, such as the randomization method or blinding procedures. Record any responses you receive and incorporate them into your assessment.

Some journals require authors to provide contact information and may facilitate communication. If you cannot reach the authors, you should note the missing information and consider how it affects your confidence in the trial.

### When to Seek Statistical Expertise

Certain aspects of risk of bias assessment require statistical expertise. For example, assessing whether missing data were handled appropriately or whether clustering was accounted for in the analysis may require consultation with a statistician. If you are conducting a systematic review as part of a team, include a statistician in the assessment process.

Statistical expertise is also needed when you plan sensitivity analyses to explore the impact of risk of bias on your findings. These analyses require careful design and interpretation.

### When to Consult Ethics Guidance

Risk of bias assessment can reveal ethical concerns about the conduct of a trial. For example, if animals were subjected to unnecessary suffering or if the trial was not approved by an ethics committee, you may need to consider whether the trial should be included in your review at all.

The [Committee on Publication Ethics](https://publicationethics.org/core-practices) provides core practices that address research conduct and publication ethics. If you suspect that a trial involved misconduct or unethical practices, you should consult the relevant guidance and consider reporting your concerns to the appropriate authorities.

## Integrating Risk of Bias with Research Planning

Risk of bias assessment is also useful for evaluating completed trials. Understanding the sources of bias can also inform the design of new research, including your own studies.

### Designing Trials to Minimize Bias

When you plan a randomized controlled trial, consider each domain of the risk of bias tool during the design phase. Use proper randomization methods with allocation concealment, plan for blinding where feasible, and pre-specify your outcomes and analyses.

Registering your trial protocol before enrollment begins can help prevent selective reporting. Trial registration also provides a public record of your planned methods, which supports transparency and allows others to assess your trial for risk of bias.

### Data Management and Sharing

Proper data management supports the assessment of risk of bias by making trial methods and data available for scrutiny. The [National Institutes of Health data management and sharing policy](https://sharing.nih.gov/data-management-and-sharing-policy) outlines expectations for planning and implementing data sharing for NIH-funded research. Even if your research is not NIH-funded, following similar practices can improve the transparency of your work.

Maintaining detailed records of your trial methods, including randomization procedures, blinding protocols, and handling of missing data, facilitates later risk of bias assessment. These records also support reproducibility and allow others to verify your findings.

### Researcher Identity and Documentation

Maintaining an accurate record of your research contributions supports the integrity of the scientific record. [ORCID](https://info.orcid.org/researchers) provides a persistent identifier that links you to your research outputs, helping to ensure that your work is correctly attributed. This is particularly important in collaborative research where multiple investigators contribute to a trial.

Clear attribution of research contributions also supports accountability for the conduct and reporting of trials. When each contributor's role is documented, it is easier to identify who is responsible for specific aspects of trial design, conduct, and analysis.

## Frequently Asked Questions

### How is risk of bias different from study quality?

Risk of bias focuses on the potential for systematic errors that could affect the results of a trial. Study quality is a broader concept that may include aspects such as the adequacy of the sample size, the appropriateness of the statistical analysis, and the completeness of reporting. A study can be well conducted but still have risk of bias if, for example, blinding was not possible for a particular outcome.

### Can a trial with high risk of bias still be useful?

A trial with high risk of bias may still provide useful information, particularly if it is the only evidence available on a question. However, you should interpret the results with caution and consider the direction and magnitude of the potential bias. Sensitivity analyses that exclude high risk of bias trials can help determine whether the conclusions are robust.

### How do I assess risk of bias when the trial report is incomplete?

When the trial report lacks essential information, you should first try to obtain the information from other sources, such as the trial protocol, registration record, or the authors. If the information cannot be obtained, you should mark the relevant signaling questions as no information and consider how this affects your domain judgment. In many cases, missing information about methods leads to a judgment of some concerns or high risk of bias.

### What is the difference between the original Cochrane tool and RoB 2?

The original Cochrane Risk of Bias tool, often called RoB 1, assessed six domains including a domain for other sources of bias. The revised tool, RoB 2, uses five domains and provides more detailed guidance for making judgments. RoB 2 also distinguishes between the effect of assignment to intervention and the effect of adhering to intervention, which is relevant when assessing trials with deviations from the protocol.

### How should I handle cluster randomized trials?

Cluster randomized trials, where groups of animals are randomized instead of individual animals, require special consideration. The risk of bias tool includes specific guidance for these trials, particularly regarding the randomization process and the analysis. You should check whether the analysis accounted for clustering and whether the effective sample size was correctly calculated.

### Can risk of bias assessment be automated?

Some tools and software can assist with risk of bias assessment, but the process requires judgment that cannot be fully automated. The signaling questions can be programmed into data collection forms, and algorithms can generate domain judgments from your answers. However, you must still read the trial reports and make decisions about the answers based on the available evidence.

### How does risk of bias assessment relate to literature review writing?

Risk of bias assessment is a core component of the methods section in a systematic review. When you write a literature review, you should describe how you assessed risk of bias, present the results of your assessments, and explain how these assessments influenced your synthesis and conclusions. This transparency allows readers to evaluate the credibility of your review

## Using the Evidence

| Source | Best use in this topic | Important limitation |
|---|---|---|
| [Research Methods Resources](https://www.ncbi.nlm.nih.gov/books) | official guidance | Check the linked page for current local requirements |
| [EQUATOR Network](https://www.equator-network.org/) | official guidance | Check the linked page for current local requirements |
| [Core Practices](https://publicationethics.org/core-practices) | official guidance | Check the linked page for current local requirements |

## Related Articles

- [Randomized Experiment Design: A Practical Guide for Reducing Bias](/blog/guides/randomized-experiment-design-a-practical-guide-for-reducing-bias)
- [Protein Synthesis Step By Step](/blog/guides/protein-synthesis-step-by-step)
- [Meta-Analysis vs Systematic Review: What's the Difference?](/blog/guides/meta-analysis-vs-systematic-review-what-s-the-difference)
- [Data Management Plan Template: A Practical Guide for Researchers](/blog/guides/data-management-plan-template-a-practical-guide-for-researchers)
- [Protein Synthesis: A Step-by-Step Guide to Transcription and Translation](/blog/guides/protein-synthesis-a-step-by-step-guide-to-transcription-and-translation)

## References and Further Reading

- [Research Methods Resources](https://www.ncbi.nlm.nih.gov/books). National Library of Medicine.
- [EQUATOR Network](https://www.equator-network.org/). EQUATOR Network.
- [Core Practices](https://publicationethics.org/core-practices). Committee on Publication Ethics.
- [NIH Grants and Funding](https://grants.nih.gov/). National Institutes of Health.
- [ORCID for Researchers](https://info.orcid.org/researchers). ORCID.
- [Data Management and Sharing Policy](https://sharing.nih.gov/data-management-and-sharing-policy). National Institutes of Health.
- [NCBI Literature Resources](https://www.ncbi.nlm.nih.gov/). National Center for Biotechnology Information.
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/). National Library of Medicine.

> This article is educational and does not replace institutional policy, professional advice, or applicable safety and regulatory requirements.